One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with <scp>SGLT2i</scp> or <scp>GLP1RA</scp>Mengqing Zhang, Linong Ji, Fang Lv et al.|Diabetes Obesity and Metabolism|2024Cited by 12
Regional, age-specific and sex-specific trends in the prevalence of overweight or obesity in type 1 diabetes from 1980 to 2020: a meta-analysis of 78 observational studies with 650,265 participantsLinong Ji, Fang Lv, Xiaoling Cai et al.|Diabetes Research and Clinical Practice|2025Cited by 3
Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?Shuzhen Bai, Linong Ji, Fang Lv et al.|European Journal of Internal Medicine|2023Cited by 1
The correlations between steady-state concentration, duration of action and molecular weight of GLP-1RAs and their efficacy and gastrointestinal side effects in patients with type 2 diabetes mellitus: a systematic review and meta-analysisRuoyang Jiao, Linong Ji, Shuzhen Bai et al.|Expert Opinion on Pharmacotherapy|2023Cited by 1
The association between the eGFR slope and cardiorenal prognosis in patients with renoprotective treatments: A systematic review and meta‐analysisShuzhen Bai, Linong Ji, Fang Lv et al.|Journal of Evidence-Based Medicine|2024Cited by 1